Morgan Stanley raises Novo Nordisk stock rating to "overweight"

The US-based investment bank spies great obesity prospects in the near future, lifting both its rating and target price for Novo Nordisk stock.

Photo: Novo Nordisk / PR

Thursday, US-based investment bank Morgan Stanley changed its stock rating for Novo Nordisk from neutral ”equal weight” to ”overweight,” reports Bloomberg News based on the bank’s analysis.

Morgan Stanley believes Novo Nordisk trading will brighten up in the future due to the potential of one of the pharmaceutical firm’s obesity drugs, Wegovy (semaglutide), to become a blockbuster, a title earned when a treatment surpasses a USD 1bn revenue threshold.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs